1. Chromosomes and Gene Expression
  2. Genetics and Genomics

Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism

  1. Ute I Scholl
  2. Gabriel Stölting
  3. Carol Nelson-Williams
  4. Alfred A Vichot
  5. Murim Choi
  6. Erin Loring
  7. Manju L Prasad
  8. Gerald Goh
  9. Tobias Carling
  10. C Christofer Juhlin
  11. Ivo Quack
  12. Lars C Rump
  13. Anne Thiel
  14. Marc Lande
  15. Britney G Frazier
  16. Majid Rasoulpour
  17. David L Bowlin
  18. Christine B Sethna
  19. Howard Trachtman
  20. Christoph Fahlke
  21. Richard P Lifton  Is a corresponding author
  1. Howard Hughes Medical Institute, Yale University School of Medicine, United States
  2. Heinrich Heine University Düsseldorf, Germany
  3. Forschungszentrum Jülich, Germany
  4. Yale Center for Mendelian Genomics, United States
  5. Yale University School of Medicine, United States
  6. Yale School of Medicine, United States
  7. Karolinska University Hospital, Sweden
  8. University of Rochester Medical Center, United States
  9. Madigan Army Medical Center, United States
  10. Connecticut Children's Medical Center, United States
  11. Intermed Consultants Ltd, United States
  12. Cohen Children's Medical Center of New York, United States
  13. NYU Langone Medical Center, United States
https://doi.org/10.7554/eLife.06315
Share this article
Cite this article
  1. Ute I Scholl
  2. Gabriel Stölting
  3. Carol Nelson-Williams
  4. Alfred A Vichot
  5. Murim Choi
  6. Erin Loring
  7. Manju L Prasad
  8. Gerald Goh
  9. Tobias Carling
  10. C Christofer Juhlin
  11. Ivo Quack
  12. Lars C Rump
  13. Anne Thiel
  14. Marc Lande
  15. Britney G Frazier
  16. Majid Rasoulpour
  17. David L Bowlin
  18. Christine B Sethna
  19. Howard Trachtman
  20. Christoph Fahlke
  21. Richard P Lifton
(2015)
Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism
eLife 4:e06315.
https://doi.org/10.7554/eLife.06315
  2. Download BibTeX
  3. Download .RIS

Abstract

Many Mendelian traits are likely unrecognized owing to absence of traditional segregation patterns in families due to causation by de novo mutations, incomplete penetrance, and/or variable expressivity. Genome-level sequencing can overcome these complications. Extreme childhood phenotypes are promising candidates for new Mendelian traits. One example is early onset hypertension, a rare form of a global cause of morbidity and mortality. We performed exome sequencing of 40 unrelated subjects with hypertension due to primary aldosteronism by age 10. Five subjects (12.5%) shared the identical, previously unidentified, heterozygous CACNA1HM1549V mutation. Two mutations were demonstrated to be de novo events, and all mutations occurred independently. CACNA1H encodes a voltage-gated calcium channel (CaV3.2) expressed in adrenal glomerulosa. CACNA1HM1549V showed drastically impaired channel inactivation and activation at more hyperpolarized potentials, producing increased intracellular Ca2+, the signal for aldosterone production. This mutation explains disease pathogenesis and provides new insight into mechanisms mediating aldosterone production and hypertension.

https://doi.org/10.7554/eLife.06315.001

eLife digest

The consequence of mutations to the large majority of human genes is unknown. Most mutations that are currently known were discovered by tracing their effects through families. This allows the locations of mutations to be pinpointed on chromosomes—the structures that genetic material is packaged into. Other mutations are harder to trace because individuals with these mutations may develop very different signs and symptoms, or not develop clinical abnormalities at all. Alternatively, a trait may appear sporadically in a family because the mutation arises anew in the affected subject.

Recently developed technologies that allow scientists to rapidly sequence all the gene-encoding regions of an individual's DNA—their genome—offer a new way to identify harmful genetic variants. Comparing the genomes of individuals with rare disorders can reveal if the individuals share any genetic mutations in common that could cause their symptoms.

Scholl et al. used this strategy to sequence the genomes of 40 individuals with a rare type of hypertension—a condition that causes high blood pressure, and increases the risk of strokes, kidney failure and heart attacks—that develops early in childhood. In this form of the disease, high blood pressure is caused by the adrenal glands above the kidneys producing too much of a hormone called aldosterone. Some genetic causes of this form of the disease have already been identified. Now, Scholl et al. have found a new genetic mutation present in five families with this condition. Two of the individuals were the first in their families to develop this mutation, while three others inherited it. Some of the family members with this mutation had hypertension and some did not.

The mutation is in a gene that encodes a type of calcium channel—a protein found in the membrane that surrounds cells, and which can open and close to control the amount of calcium in the cell. This particular calcium channel is abundant in the cells of the adrenal gland. Scholl et al. found that the mutation causes the calcium channels to be more likely to open and take longer to close. This increases the number of calcium ions that move into the cell, which causes the adrenal gland to produce more aldosterone. These new insights have provided a new way of diagnosing early-onset hypertension, and suggest that targeting calcium channels could help to develop new treatments for this disease.

https://doi.org/10.7554/eLife.06315.002

Introduction

The steroid hormone aldosterone is normally produced in the adrenal zona glomerulosa in response to either angiotensin II, which is produced in response to volume depletion, or hyperkalemia (high plasma K+ level). Both stimuli cause membrane depolarization, activating voltage-gated Ca2+ channels; increased intracellular Ca2+ provides the signal that triggers aldosterone production (Spät and Hunyady, 2004). In the setting of volume depletion, aldosterone signaling in renal and intestinal epithelia produces increased salt (re)absorption, promoting restoration of intravascular volume; in hyperkalemia, aldosterone promotes increased potassium secretion, restoring electrolyte balance.

Pathological secretion of aldosterone in the absence of normal physiological stimuli leads to primary aldosteronism (PA), producing increased salt (re)absorption and hypertension. Hypokalemia is a frequently associated finding, resulting from increased renal K+ elimination. PA is found in 10% of patients referred for evaluation of hypertension (Conn, 1955; Rossi et al., 2006). About half of these patients have adrenal aldosterone-producing adenomas (APAs). Germline mutations in three genes have been shown to cause rare Mendelian forms of early-onset PA. Gene fusions leading to constitutive expression of aldosterone synthase (encoded by CYP11B2), a rate-limiting enzyme in aldosterone biosynthesis, cause Glucocorticoid-Remediable Aldosteronism (GRA) (Lifton et al., 1992). Mutations in and near the selectively filter of the K+ channel encoded by KCNJ5 result in channels that conduct Na+, leading to adrenal glomerulosa cell depolarization and activation of Ca2+ channels, producing a Mendelian form of aldosteronism (Choi et al., 2011). Gain of function mutations in the calcium channel encoded by CACNA1D cause increased Ca2+ channel activity and another form of PA. These latter patients also have seizures, neurodevelopmental and neuromuscular abnormalities owing to gain of function effects of CACNA1D in the nervous system (Scholl et al., 2013). Families with GRA often have many affected subjects and were identified by linkage analysis in extended families (Lifton et al., 1992). Germline mutations in KCNJ5 are typically de novo or in small nuclear families; similarly, CACNA1D mutations to date are all de novo (Choi et al., 2011; Scholl et al., 2012, 2013). Germline mutations in KCNJ5 and CACNA1D were found following identification of the same or related somatic mutations as drivers of APAs (Choi et al., 2011; Scholl et al., 2012; Azizan et al., 2013; Scholl et al., 2013).

The causes of PA in many patients remain undetermined. Although Mendelian inheritance has been suggested by recurrence of PA in some kindreds without mutations in known genes (Stowasser et al., 1992; Torpy et al., 1998; Lafferty et al., 2000), traditional linkage analysis has failed to identify additional causative genes, likely due to a combination of factors including locus heterogeneity, high frequency of de novo mutations, reduced penetrance and/or variable expressivity. The advent of next-generation sequencing, allowing the search for recurrent mutations or greater burden of rare variants in individual genes than expected by chance, can permit identification of such loci in the absence of classical segregation patterns. Very rare phenotypes, such as childhood PA, are promising candidates for such traits.

Using exome sequencing, we here identify five independent occurrences of the identical mutation in CACNA1H among 40 subjects with unexplained PA in childhood. CACNA1H encodes a voltage-gated calcium channel that is expressed in adrenal glomerulosa. Electrophysiology demonstrates that this variant causes reduced inactivation and a shift of activation to more hyperpolarized potentials, effects inferred to produce increased calcium influx and PA.

Results

Whole-exome sequencing of 40 subjects with PA

From a cohort of more than 1500 unrelated subjects referred for evaluation of genetic forms of hypertension, we identified 40 subjects diagnosed with hypertension and PA by age 10 years in whom disease-causing mutations in CYP11B2, KCNJ5, and CACNA1D (Lifton et al., 1992; Choi et al., 2011; Scholl et al., 2013) were excluded. Clinical details are shown in Supplementary file 1A. All subjects had hypertension with elevated aldosterone levels despite low plasma renin activity (PRA). None of the subjects studied were the offspring of consanguineous union. DNA from peripheral blood was subjected to exome capture and sequencing; mean coverage was 73 independent reads per targeted base (Supplementary file 1B). Variants were called as described in ‘Materials and methods’ (Lemaire et al., 2013).

We performed three analyses tailored to the expectation of a rare genetic disease (‘Materials and methods’). We sought previously unreported (absent in dbSNP, NHLBI, 1000Genomes and Yale exome databases) protein-altering variants that occurred in more than one subject (Supplementary file 1C); we performed gene burden analyses to search for previously unreported or rare (minor allele frequency [MAF] < 0.01%) heterozygous variants that collectively occurred in any gene more often than expected by chance (Supplementary file 1D); we searched for rare (MAF < 0.1%) homozygous and potential compound heterozygous variants that collectively occurred in any genes more often than expected by chance (Supplementary file 1E).

Identification of a recurrent novel variant in CACNA1H

There was only one result that surpassed genome-level significance: we found five apparently unrelated subjects with the identical previously unreported heterozygous A > G variant, resulting in a p.Met1549Val substitution in CACNA1H, which encodes the pore-forming alpha subunit of a T-type, low voltage-activated calcium channel (aka CaV3.2) (Figure 1, Table 1, Supplementary file 1F) (Perez-Reyes, 2003). This variant is absent among more than 129,000 alleles sequenced from diverse populations in the Exome Aggregation Consortium (Exome Aggregation Consortium), and Yale databases. No other CACNA1H alleles with allele frequencies <0.01% were found among our cohort. Like other Ca2+ channel alpha subunits, CACNA1H contains four homologous repeats (I–IV), each with six transmembrane segments (S1–S6). The CACNA1HM1549V variant lies in the S6 segment of repeat III (Marksteiner et al., 2001). Sanger sequencing in each case confirmed the heterozygous variant (Figure 1A).

Figure 1 with 1 supplement see all
Download asset Open asset
Kindreds with hypertension and primary aldosteronism (PA) with CACNA1HM1549V mutation at conserved position of S6 domain.

(A) Pedigrees of kindreds with CACNA1HM1549V mutation are shown. Studied subjects with early-onset hypertension are shown as black filled symbols, and subjects with early-onset hypertension by family history (K333) or low renin with normal blood pressure (K1393) are shown as grey filled symbols. Genotypes are indicated below each symbol (+/+ denotes wild type sequence; +/M denotes heterozygosity for CACNA1HM1549V variant). Corresponding Sanger sequencing results for selected subjects are depicted to the right. (B) Transmembrane structure of CaV3.2 (encoded by CACNA1H), the pore-forming subunit of a voltage-gated Ca2+ channel, is shown. These channels have four internal homologous repeats (I–IV), each with six transmembrane segments (S1–S6) and a membrane-associated loop between the pore-forming S5 and S6 segments. The p.Met1549Val mutation is located in S6 of repeat III. (C) Conservation of CACNA1HM1549 in CACNA1H orthologs and paralogs. The amino acid sequences of the S6 segment of domain III of CACNA1H, orthologs and paralogs are shown. The S6 segment, including Met1549, is virtually completely conserved (highlighted in yellow) among orthologs and all paralogs that are activated by small changes in membrane potential (l, low voltage-activated) but not those activated by large changes (h, high voltage-activated). M1549 is part of the Met-Phe-Val sequence that is implicated in rapid channel inactivation (Marksteiner et al., 2001).

https://doi.org/10.7554/eLife.06315.003
Figure 1—source data 1

Source data corresponding to Figure 1.

https://doi.org/10.7554/eLife.06315.004
Table 1

Clinical features of index cases with CACNA1HM1549V

https://doi.org/10.7554/eLife.06315.006
Subject IDGenderAge dxBP (%ile)Aldo (ng/dl)PRA (ng/ml/hr)ARR (ng/dl: ng/ml/hr)
1347-1M3 yrs160/105 (>99th)20<0.1>200
1390-1F7 yrs150/90 (>99th)660.2330
1368-1M8 yrs140/90 (>99th)20<0.2>100
333-2M9 yrs192/144 (>99th)40<0.7>57
1393-1M2 mos170/110 (>99th)87<0.6>145

  1. M, male; F, female; age dx, age at diagnosis of hypertension; yrs, years; mos, months; BP, blood pressure; (%ile), percentile adjusted for age and gender; Aldo, serum aldosterone; PRA, plasma renin activity; ARR, aldosterone:renin ratio, values >20 with aldosterone level >15 are considered indicative of primary aldosteronism (PA).

Three index cases were of European ancestry, one Hispanic, and one African American by self-report and principal component analysis (Figure 1—figure supplement 1). Members of the extended families were recruited, and sequencing of these subjects demonstrated that CACNA1HM1549V was a de novo mutation (absent in the biological parents) in both the index case of kindred 1347, and in the affected mother of the index case in kindred 1390 (Figure 1). Analysis of highly polymorphic markers confirmed paternity and maternity in both kindreds (Supplementary file 1G). This establishes independent occurrences of CACNA1HM1549V in these two kindreds. In the remaining three kindreds, the variant was transmitted to the index case from a parent, and samples from grandparents were not available for further analysis of transmission (Figure 1). Analysis of kinship coefficients using SNP genotypes of affected subjects from Illumina Human 1M-Quad beadchips and the KING algorithm (Manichaikul et al., 2010) provided no evidence that these three kindreds shared recent common ancestry (Supplementary file 1H, ‘Materials and methods’). Further, haplotypes flanking the CACNA1H mutation were phased using the BEAGLE program, revealing that the maximum shared haplotype flanking the CACNA1H mutation among these three kindreds was only 53.6 kb (87.0 kb for the two European kindreds, Figure 2). From this data, the maximum likelihood estimate of the number of generations since the last shared common ancestor among these subjects is estimated to be 714 generations 95% CI 290-1268 (Genin et al., 2004). A more conservative analysis identifying homozygous discordant SNPs (eliminating inference of haplotypes by phasing) still limited the shared haplotype to less than 127.1 kb, consistent with the results of phasing using BEAGLE. These findings indicate that the CACNA1HM1549V mutation in these three kindreds has not been inherited from a recent common ancestor, and has either arisen independently or has been inherited from an extremely remote common ancestor. The latter possibility is extremely unlikely given the absence of this mutation in more than 129,000 alleles studied to date.

Figure 2
Download asset Open asset
Shared haplotypes in subjects with inherited CACNA1HM1549V variant.

Haplotypes of three affected individuals from kindreds without proven de novo occurrence of CACNA1HM1549V variant were phased using BEAGLE (‘Materials and methods’) (Browning and Browning, 2007). This analysis identified a very small maximum interval shared among all three individuals (∼53.6 kb, green box) flanked by rs1075789 and rs3760122. If only homozygous discordant calls (*) were considered in the absence of phasing, the maximum interval shared by all three subjects would be 127.1 kb and the longest pairwise shared haplotype would be 200.0 kb between 1393-1 and 333-1.

https://doi.org/10.7554/eLife.06315.007

The probability of finding any recurrent protein-altering de novo mutation among 40 kindreds is ∼4.0 × 10−6 (see ‘Materials and methods’). Even with a conservative estimate of the allele frequency of CACNA1HM1549V of 0.00001 in the general population (‘conservative’ because it has never been seen among >129,000 alleles in subjects not selected for early PA), the probability of finding three additional instances of this mutation in 38 unrelated subjects is ∼8.4 × 10−12. Combined, the probability of finding these five instances of the identical variant by chance is conservatively estimated to be 3.4 × 10−17, providing extremely strong statistical support for the role of this mutation in PA.

CACNA1H is expressed in human adrenal glomerulosa

If the CACNA1HM1549V mutation causes early-onset PA, CACNA1H (CaV3.2) should be expressed in human adrenal glomerulosa. CACNA1H transcripts have previously been reported in human kidney, liver, heart and brain (Cribbs et al., 1998), and our prior analysis of gene expression of human adrenal cortex showed that CACNA1H was the second most highly expressed calcium channel alpha subunit, after CACNA1D (Scholl et al., 2013). We performed immunohistochemistry with two different antibodies specific for the encoded channel protein (CaV3.2), demonstrating strong staining of human adrenal glomerulosa; this staining was abolished after preincubation with immunogenic peptide (Figure 3). These results are consistent with prior in situ hybridization and electrophysiological studies of rodent and bovine glomerulosa (Schrier et al., 2001; Hu et al., 2012) as well as a recent study of human adrenal gland (Felizola et al., 2014).

Figure 3
Download asset Open asset
Immunohistochemistry of CaV3.2 in normal human adrenal gland.

Sections of normal human adrenal are shown. C denotes adrenal capsule; G, glomerulosa; F, fasciculata. (A) Normal adrenal gland stained with hematoxylin and an antibody to CaV3.2 (Alomone). (B) Higher power image of adrenal in panel (A). (C, D) Absence of staining after preincubation of the antibody with the antigenic peptide, demonstrating specificity. (E) A second normal human adrenal gland stained for CACNA1H as in (A, B). (F) Gland from (A–D) stained with a second α-CACNA1H antibody (Santa Cruz). Scale bars, 100 μm (A, C); 50 μm (B, D, E, F). The results demonstrate expression of CaV3.2 in the normal zona glomerulosa, which is only several cells in depth.

https://doi.org/10.7554/eLife.06315.008

Clinical features of subjects with CACNA1HM1549V variant

The clinical features of the index cases harboring the CACNA1HM1549V variant were uniform. All presented with hypertension by age 10 and had persistent inappropriate elevation of serum aldosterone with suppressed PRA and high aldosterone:PRA ratio, indicative of autonomous adrenal aldosterone production (Table 1). Adrenal imaging by computed tomography, magnetic resonance or ultrasound showed no evidence of mass or hyperplasia at the time of presentation. There were no other recurrent or distinctive features of the index cases, specifically no history of seizures, neurologic or neuromuscular disorders as found in patients with CACNA1D mutations (Scholl et al., 2013). Additional details are presented in Appendix 1.

By direct Sanger sequencing, we identified five additional CACNA1HM1549V mutation carriers among family members, including four parents and one uncle of an index case (Figure 1). Of these five, three were diagnosed with early severe hypertension while two were not, and in fact were normotensive as adults (Appendix 1 and Supplementary file 1I). For example, subject 1390-2 was diagnosed with severe hypertension and PA at age 17; her hypertension was difficult to control, leading to unilateral adrenalectomy at age 29. Her hypertension nonetheless recurred, requiring reinstitution of treatment. Interestingly, the histology of her adrenal gland showed striking microscopic hyperplasia. While the normal adrenal glomerulosa comprises only a few cell layers and is about 70 μm in depth, the glomerulosa of subject 1390-2 was ∼30 cell layers and ∼300 μm in depth (Figure 4A–C). CACNA1H was expressed in the hyperplastic glomerulosa layer (Figure 4, Appendix 1). In this kindred, the CACNA1HM1549V variant arose concordantly and segregated precisely with PA and early hypertension (Table 2). Two mutation carriers (1368-2 and 1393-3) were normotensive as adults and had not been diagnosed as hypertensive in childhood; in subject 1393-3, PRA was at the lower limit of normal with normal aldosterone level, while PRA and aldosterone levels were normal in 1368-2 (Supplementary file 1I).

Figure 4
Download asset Open asset
Glomerulosa hyperplasia in adrenal gland of subject 1390-2 with CACNA1HM1549V mutation.

C denotes adrenal capsule; G, glomerulosa; F, fasciculata; R, reticularis; M, medulla. (A) Low power image stained with hematoxylin and eosin. Scale bar 1000 μm. (B, C) Higher power images of adrenal from panel (A), scale bars 400 μm (B) or 100 μm (C). The mutant adrenal shows marked zona glomerulosa hyperplasia, with micronodular invasion of the capsule (denoted by *). (D) Same adrenal gland stained with hematoxylin and antibody to CaV3.2 (Santa Cruz), demonstrating specific staining of zona glomerulosa. Scale bar, 400 μm. (E, F), higher power images stained with second antibody to CaV3.2 (Alomone). Scale bars 250 μm (E) or 100 μm (F). CaV3.2 is expressed in the hyperplastic zona glomerulosa.

https://doi.org/10.7554/eLife.06315.009
Table 2

Laboratory values of carriers and non-carriers of CACNA1HM1549V in kindred 1390

https://doi.org/10.7554/eLife.06315.010
Subject IDGenderAge (yrs)K+ (mmol/l)Aldo (ng/dl)PRA (ng/ml/hr)ARR (Aldo/PRA)Direct renin (μIU/ml)Aldo/direct renin
Carriers
 1390-1F153.7370.4288.1NANA
 1390-2F293.522NANA37.3
Non-Carriers
 1390-4M174.321.651.2NANA
 1390-8M373.8<12.25<0.4NANA
 1390-5F624.11618.920.8NANA
 1390-6F514.041.872.1NANA
 1390-7F464.331.671.8NANA

  1. M, male; F, female; Age (yrs), Age in years when sample was obtained; K+, serum potassium (reference 3.5–5.5 mmol/l); Aldo, serum aldosterone; PRA; direct renin <5 is indicative of volume-mediated hypertension; ARR, aldosterone:renin ratio, values >20 (using PRA) or values of aldo/direct renin >2.4 with aldosterone level greater than 15 are considered indicative of PA. Blood samples were drawn on the same day, and values were determined in the same laboratory (except for 1390-2, in whom values are pre-adrenalectomy at age 29). See Figure 1 for relationships. 1390-6 and −7 are not included in Figure 1, and are sisters of 1390-5.

Specificity of CACNA1HM1549V variant for early-onset PA

To explore the specificity of this mutation for early-onset PA, we performed targeted Sanger sequencing for the CACNA1HM1549V variant in germline DNA of 1632 additional unrelated subjects, comprising 324 subjects with PA diagnosed after age 10 years, 96 with hypertension and bilateral adrenal hyperplasia, and 1212 referred for potential genetic causes of hypertension without evidence of PA. We also sequenced tumor DNA of 90 APAs, including 40 that did not have mutations in previously implicated genes (KCNJ5, CACNA1D, ATP1A1, ATP2B3, and CTNNB1 [Choi et al., 2011; Azizan et al., 2013; Beuschlein et al., 2013; Scholl et al., 2013]). No additional CACNA1HM1549V mutations were identified, demonstrating striking specificity for early-onset PA.

CACNA1HM1549 lies in a conserved MFV motif

Members of the CaV3 family are activated by small depolarizing changes in the membrane potential (activation threshold ∼ −60 mV) and display very fast voltage-dependent inactivation (Perez-Reyes, 2003). Methionine at the position corresponding to CACNA1HM1549 is conserved in the S6 helix of repeat three in all identified orthologs, including invertebrates. In addition, methionine occurs at the paralogous position in other calcium channels activated by small depolarizing potential changes (Figure 1C). Prior studies of CaV3.1 (CACNA1G) have shown that methionine 1549 lies in a methionine-phenylalanine-valine (MFV) tripeptide that regulates channel inactivation (Hering et al., 1998; Marksteiner et al., 2001). Mutation of the homologous methionine in CaV3.1 to isoleucine or alanine results in delayed channel inactivation (Marksteiner et al., 2001), and related calcium channels with isoleucine at the homologous position inactivate more slowly than those with methionine (Hering et al., 1997) (Figure 1C).

CACNA1HM1549V causes loss of normal inactivation

To assess the biophysical properties of CACNA1HM1549V, we heterologously expressed either CACNA1HWT or CACNA1HM1549V in HEK293T cells and performed whole-cell patch clamp recordings (Figure 5A). Upon depolarizing voltage steps from −90 mV, CACNA1HWT showed fast activation of calcium currents followed by rapid inactivation, consistent with prior studies (Cribbs et al., 1998). In contrast, CACNA1HM1549V exhibited marginally slower activation followed by a dramatically slowed inactivation. While CACNA1HWT is virtually fully inactivated by 400 ms, CACNA1HM1549V shows strong tail currents after returning to the holding potential of −90 mV (Figure 5A), demonstrating loss of normal inactivation, an effect still evident after sustained depolarization for 5 s (Figure 5B).

Figure 5 with 1 supplement see all
Download asset Open asset
CACNA1HM1549V impairs channel inactivation.

Whole-cell patch clamp recordings were performed in HEK293T cells transfected with CACNA1HWT or CACNA1HM1549V. (A) Cells were held at −90 mV, and voltage steps between −90 and +50 mV were applied to elicit calcium currents, followed by a step to −90 mV to evoke tail currents. Representative recordings show rapid activation and inactivation of CACNA1HWT currents and delayed inactivation of CACNA1HM1549V. Tail currents are exclusively present in CACNA1HM1549V and suggest the presence of non-inactivated mutant channels at the end of the depolarizing pulse. (B) Tail currents are still present after a 5-s pulse to −20 mV. The fraction of non-inactivated channels after 5 s was determined by dividing the peak amplitude at −20 mV before and after 5 s long pulses to voltages between −90 and −20 mV in 5 mV increments (CACNA1HM1549V: 6.7 ± 1%, N = 12; CACNA1HWT: 2.4 ± 0.5%, N = 9; p = 0.004, protocol not shown in figure). (C) Exponential fits of the current decay between −50 and +30 mV provide inactivation time constants. Data from CACNA1HM1549V are shown in blue circles, CACNA1HWT data are shown in red squares. The mutant channel shows almost 10-fold slower inactivation than wild-type (N = 9 for CACNA1HWT, N = 7–14 for CACNA1HM1549V, p < 0.001 across all voltages studied, Mann–Whitney rank sum test). (D) In contrast, activation time constants at different voltages are only slightly slower in CACNA1HM1549V compared to WT (cf. ‘Materials and methods’ for details). Source files are available in Figure 5—source data 1.

https://doi.org/10.7554/eLife.06315.011
Figure 5—source data 1

Source data corresponding to Figure 5.

https://doi.org/10.7554/eLife.06315.012

We fitted mono-exponential equations to the decay phase of the calcium current between −50 mV and +30 mV. The determined time constants represent the mean time at which the current has decreased to 1/e of its initial amplitude; the results demonstrate ∼10-fold slower inactivation of CACNA1HM1549V compared to CACNA1HWT (p < 0.001 at all voltages studied, Figure 5C). In contrast, activation and recovery from inactivation were only marginally slower in mutant channels (Figure 5D, Figure 5—figure supplement 1).

CACNA1HM1549V leads to a shift of activation to less depolarizing potentials

We also observed a significant shift of activation to less depolarizing potentials (Figure 6). CACNA1HWT showed half-maximal activation (V1/2 ) at −38.9 ± 1.1 mV (N = 11); in contrast, CACNA1HM1549V showed V1/2 of −44.2 ± 1.1 mV (N = 11, p = 0.003), resulting in a lower threshold for activation and increase in size of the ‘window current’, the area under the intersection of activation and inactivation curves where a fraction of channels are constitutively open. There was no significant effect on single channel conductance (Figure 6—figure supplement 1).

Figure 6 with 1 supplement see all
Download asset Open asset
CACNA1HM1549V shifts activation to more hyperpolarized potentials.

(A) Current-voltage plots and (B) activation curves show a shift of V1/2 for activation of the mutant channel to less depolarizing potentials. The voltage dependence of inactivation is shown as open circles or squares. For CACNA1HM1549V, the area under the intersection of activation and inactivation curves (where a fraction of channels show continuous activity) is larger and shifted to more hyperpolarized potentials compared to CACNA1HWT, allowing for increased constitutive Ca2+ influx at potentials close to the resting potential of zona glomerulosa cells (Hu et al., 2012). Source files are available in Figure 6—source data 1.

https://doi.org/10.7554/eLife.06315.014
Figure 6—source data 1

Source data corresponding to Figure 6.

https://doi.org/10.7554/eLife.06315.015

Collectively, the changes in inactivation and voltage-dependence of activation cause Ca2+ influx at membrane potentials close to the resting potential and result in channels that remain open longer, allowing increased Ca2+ entry.

Discussion

These findings define a previously unrecognized form of PA resulting from a recurrent germline gain of function mutation in the Ca2+ channel encoded by CACNA1H. The extremely strong statistical evidence implicating this mutation, its clear gain of function effect, and the known role of Ca2+ signaling on aldosterone production and cell proliferation (Spät and Hunyady, 2004) all strongly support this conclusion. The effects of this mutation phenocopy the adrenal effects of PA-causing mutations in KCNJ5 (Choi et al., 2011) and CACNA1D (Scholl et al., 2013), demonstrating a shared final common pathway by which PA results from increased Ca2+ entry via voltage-gated channels. These results allow a simple genetic test for this specific cause of severe hypertension and suggest that inhibition of mutant CACNA1H activity would ameliorate hypertension in patients with this mutation. While the CACNA1HM1549V mutation explains a significant fraction of the early PA cases, the causes of the remaining cases in our cohort are still unknown.

There is striking genotype–phenotype correlation among patients with germline and somatic mutations in KCNJ5 and CACNA1H. Several recurrent germline mutations in KCNJ5 (e.g., p.Gly151Arg and p.Thr158Ala) support robust cell proliferation leading to massive adrenal hyperplasia identifiable on CT scan, leading to adrenalectomy (Choi et al., 2011; Scholl et al., 2012). In contrast, another recurrent mutation in KCNJ5 (p.Gly151Glu) shows no or minimal hyperplasia discernable by adrenal imaging (Mulatero et al., 2012; Scholl et al., 2012). While the former mutations are also found as somatic mutations in about 40% of APAs (Choi et al., 2011; Mulatero et al., 2012), the latter have not been found in more than 900 APAs (Scholl and Lifton, 2013). This phenotypic difference is likely accounted for by different effects on Na+ conductance- the germline mutations that are not associated with APAs or hyperplasia cause markedly greater Na+ conductance, resulting in very high cell lethality, preventing sustained increases in cell mass (Mulatero et al., 2012; Scholl et al., 2012). Similarly, adrenal glands with CACNA1HM1549V show little or no hyperplasia by CT scan and neither this mutation nor other activating mutations in CACNA1H have been seen in APAs. We have not observed high cell lethality in HEK293T cells expressing CACNA1HM1549V. Germline mutations that cause massive hyperplasia and somatic mutations that cause APA formation likely require an optimal Ca2+ signal, one that is high enough to support proliferation but not so high as to cause cell lethality (Berridge et al., 2000).

While germline mutations in KCNJ5 and CACNA1D were discovered following the initial identification of their somatic mutations in APAs (Choi et al., 2011; Scholl et al., 2013), the discovery of the recurrent CACNA1H mutation relied entirely on brute force sequencing of patients with early severe aldosteronism and hypertension. The occurrence of de novo mutations, the reduced penetrance in adults with the absence of large multiplex families, as well as the absence of distinctive phenotypes that distinguish these patients from others with early hypertension and aldosteronism, all suggest reasons that CACNA1H mutations were not previously linked to PA.

The reduced penetrance in adults in particular is interesting—two mutation-carrier parents were normotensive as adults, without clear evidence of PA. Incomplete penetrance among some carriers of mutations that cause aldosteronism (Stowasser et al., 1995; Mulatero et al., 2002; Scholl et al., 2013) has been previously described. The explanations for these effects remain unclear, however age-dependent activity of the renin-angiotensin system and the ability of older individuals to modulate dietary salt intake in response to physiologic demand are potential contributors. This is well described in the case of heterozygous loss of function mutation in the receptor for aldosterone (the mineralocorticoid receptor, MR). These patients have life-threatening salt-wasting and volume depletion in the first years of life due to low signaling through MR, but are asymptomatic as adults. Adult subjects show increased dietary salt intake and increase MR signaling by induction of the renin-angiotensin system, thereby markedly increasing aldosterone levels (Geller et al., 1998). Other possible mechanisms for incomplete penetrance include genetic modifiers either in cis or in trans, including the possibility of somatic mosaicism resulting in absence of the gain of function mutation the adrenal gland (Youssoufian and Pyeritz, 2002). While such mosaicism cannot be excluded, Sanger sequence traces provided no suggestion of mosaicism in circulating white blood cell or saliva DNA (Figure 1A).

CACNA1HM1549V shows constitutive activity at membrane potentials close to the resting potential, allowing channels to be activated despite suppression of the renin-angiotensin system and absence of hyperkalemia. CACNA1HM1549V channels also show strikingly delayed inactivation, a finding similar to mechanisms in several other channelopathies (Cannon et al., 1991; Lerche et al., 1993; Scholl et al., 2013). In glomerulosa, delayed inactivation is inferred to increase the period of membrane potential depolarizations. Interestingly, recent studies in mouse have implicated CACNA1H activity in regular glomerulosa membrane potential oscillations that may amplify small changes in membrane potential to produce significant Ca2+ signals (Hu et al., 2012). Thus this regular activation of CACNA1H, together with a shift of activation to less depolarized potentials and prolonged activity, provides a mechanism for increased Ca2+ entry, leading to aldosteronism. While a common variant in CACNA1H has been suggested to be associated with blood pressure in a small genome-wide association study of African American individuals (Adeyemo et al., 2009), this result did not pass criteria for genome-wide significance, was only found after exclusion of hypertensive individuals, and was not replicated in larger studies (International Consortium for Blood Pressure Genome-Wide Association Studies et al., 2011; Kidambi et al., 2012).

The apparent limitation of the phenotype associated with CACNA1HM1549V to PA with hypertension despite the expression of CACNA1H in other organs including heart and brain (Cribbs et al., 1998) is notable, and underscores the challenges in predicting human phenotypes from knowledge of underlying mutations. No mutation carrier had a history of seizures or cardiac arrhythmia. While some prior studies have suggested a role of rare gain of function mutations in CACNA1H in epilepsy (Chen et al., 2003; Liang et al., 2006; Heron et al., 2007), these studies have not approached genome-wide levels of significance, do not appear to confer high risk, and have not been uniformly replicated (Heron et al., 2004; Chioza et al., 2006; Liang et al., 2006).

Our findings are consistent with evidence supporting a normal role for CACNA1H in the regulation of human aldosterone biosynthesis (Felizola et al., 2014). Because CACNA1H is activated by small depolarizing changes in glomerulosa membrane potential, it is likely activated in response to small day-to-day changes in serum K+ concentration and angiotensin II levels that require fine adjustments in aldosterone production to maintain volume and electrolyte balance. In contrast, CACNA1D, which is the most highly expressed calcium channel in adrenal cortex, and which shows larger single channel conductance than CACNA1H (Michels et al., 2002; Bock et al., 2011), is only activated by large depolarizations. Activation of this channel likely contributes to the high levels of aldosterone produced in response to marked volume depletion or hyperkalemia. We suggest that CACNA1H and CACNA1D act in series in the regulation of aldosterone, with CACNA1H being activated in response to small, frequent physiologic perturbations and CACNA1D in response to more infrequent large physiologic challenges.

These findings also raise the question whether inhibition of wild type CACNA1H would lower blood pressure or aldosterone production. In the general population, loss-of-function variants in CACNA1H are very rare (cumulative frequency of splice site, frameshift and nonsense variants in the ExAC database of 0.06%, resulting in expected compound heterozygosity or homozygosity in about 1 in 2.6 million subjects), making such studies challenging. It seems plausible that loss of CACNA1H could be compensated by activation of the renin-angiotensin system, leading to greater glomerulosa cell depolarization with consequent activation of CACNA1D, maintaining normal aldosterone production and blood pressure. Consistent with this suggestion, blood pressure was reportedly unchanged in a CACNA1H knockout mouse model, although aldosterone levels were not reported (Chiang et al., 2009). Similarly, selective inhibitors of CACNA1H inhibit aldosterone production in vitro (Rossier et al., 1998; Perez-Reyes et al., 2009), but do not apparently reduce aldosterone levels or blood pressure in vivo (Schmitt et al., 1992; Ragueneau et al., 2001). Whether additional non-dihydropyridine compounds will prove to be more effective in lowering aldosterone levels or blood pressure will be interesting to assess.

Materials and methods

Subjects

PA was diagnosed based on elevated ARR (>20 ng/dl:ng/ml/hr), typically with aldosterone >15 ng/dl, or marginally elevated values in the presence of unexplained hypokalemia (Funder et al., 2008). Venous blood or saliva samples were obtained from subjects with unexplained early-onset PA and family members. Research protocols were approved by the local institutional review board (IRB), and informed consent was obtained from all research participants.

DNA preparation, and exome sequencing

Request a detailed protocol

DNA was prepared from venous blood or saliva samples using standard procedures. Exome capture was performed using the 2.1M NimbleGen Exome reagent (Roche NimbleGen, Madison, WI), and 75 base paired end sequencing on the Illumina (San Diego, CA) platform was performed as previously described (Lemaire et al., 2013). Coverage statistics are provided in Supplementary file 1B.

Sanger sequencing of genomic DNA and genotyping of parent-offspring trios

Request a detailed protocol

Direct bidirectional Sanger sequencing of CACNA1HP1523-R1584 from genomic DNA of indicated subjects was performed following PCR amplification using primers

CACNA1H_25F (5′-GACCCACCGCCTCTGTG-3′) and CACNA1H_25R (5′-AGCGCCTTACTCCTGCG-3′).

Parent-offspring trios were genotyped as previously described, except for locus D7S820 in kindred 1390 (primers [5′-ATGTTGGTCAGGCTGACTATG-3′] and [5′-GATTCCACATTTATCCTCATTGAC-3′]) (Scholl et al., 2013). Alleles without known frequencies in the population were omitted from the analysis.

Immunohistochemistry

Request a detailed protocol

Normal human adrenal tissue was obtained from the Yale Pathology archive, and adrenal tissue from subject 1390-2 from Pathology Services of Beaufort/Charleston (South Carolina, USA). Immunohistochemistry was performed as previously described (Scholl et al., 2013). Primary antibodies were α-CaV3.2 (#ACC-025, Alomone, Jerusalem, Israel) or T-type Ca++ CP α1H (SC-25691, Santa Cruz Biotechnology, Santa Cruz, CA), both at dilutions of 1:100; secondary antibody was donkey α-rabbit (#035-152, 1:500, Jackson, Bar Harbor, ME). For the Alomone antibody, preincubation with the antigenic peptide (1:1, wt/wt in 10% FBS) was performed for 1 hr at RT. Both antibodies were tested on two independent glands. H&E staining was performed at Yale Research Histology using routine procedures.

Molecular cloning

Request a detailed protocol

Myc-DDK-tagged CACNA1H in pCMV6-Entry was obtained from Origene (Rockville, MD) (RC212772, NM_021098.2). Site-directed mutagenesis (QuikChange, Agilent Technologies, Santa Clara, CA) was performed to introduce the p.Met1549Val mutation according to the manufacturer's instruction. Each construct was validated by sequencing of the entire coding region.

Transient transfection and electrophysiological recordings

Request a detailed protocol

Culturing of HEK293T cells was performed as described (Scholl et al., 2013). Cells were transfected with 3 µg of CACNA1HWT or CACNA1HM1549V expression plasmids. For each construct, two clones were functionally tested. Whole cell patch clamp recordings were performed on a HEKA EPC10 amplifier (HEKA Elektronik, Ludwigshafen, Germany) as described previously (Scholl et al., 2013). The extracellular solution contained: 5 mM CaCl2, 125 mM TEA-Cl, 10 mM HEPES, 15 mM Mannitol, pH 7.4. Pipette solution contained: 100 mM CsCl, 5 mM TEA-Cl, 3.6 mM PCr-Na2, 10 mM EGTA, 5 mM Mg-ATP, 0.2 mM Na-GTP, 10 mM HEPES, pH 7.4 (titration with CsOH).

Voltage dependences of activation were determined from the peak current–voltage relation and fit by a Boltzmann function as described (Marcantoni et al., 2010; Scholl et al., 2013). The fraction of non-inactivated channels was determined by dividing the peak amplitude at −20 mV before and after 5 s long pulses to voltages between −90 and −20 mV. Time courses of activation or inactivation were analyzed by fitting a mono-exponential function (Scholl et al., 2013). The recovery from inactivation was measured using envelope protocols consisting of an inactivation of channels during a 5 s pulse to −20 mV followed by holding the membrane potential at −90 for increasing durations (Coulter et al., 1989). Afterwards, peak currents at −20 mV were measured and divided by the previous peak current. A plot of these ratios vs the duration of the pulse to −90 mV was fit with a mono-exponential function to obtain time constants for the recovery from inactivation.

Non-stationary noise analysis was performed as described (Hebeisen and Fahlke, 2005) using a voltage protocol that activates channels at −20 mV followed by the analysis of the decay of currents and variance at −90 mV. The initial variance at the holding potential of −90 mV before activation was regarded as background variance and subtracted from the recordings. The Lorentzian noise produced by channel opening and closing depends on the unitary current amplitude (i), the number of channels (N), and the absolute open probability (P):

(1) σ2=N·i2·p·(1−p).

Since the macroscopic current amplitude is given by

(2) I=N·p·i,

the variance-current relationship results in a quadratic distribution:

(3) σ2=i·〈I〉−(〈I〉2N).

The single channel amplitude (i) was derived from the initial slope of a plot of the variance against the mean isochronal current results. Due to a low open probability (p < 0.5) at 5 mM of external Ca2+, the recorded data points only described a small part of the usual parabola and did not allow for determination of the number of channels and open probabilities.

Data were analyzed in FitMaster (HEKA Elektronik), SigmaPlot (Jandel Scientific, San Rafael, CA) and Python. Statistical comparisons were performed using Student's t-test or Mann–Whitney rank sum test.

Orthologs and paralogs

Request a detailed protocol

Proteins encoded by orthologs or close paralogs of CACNA1H in vertebrate and invertebrate species were identified by a BLAST search. GenBank accessions included NP_066921.2 (Homo sapiens), O88427.3 (Mus musculus), XP_414830.4 (Gallus gallus), XP_002932520.2 (Silurana tropicalis), XP_002122425.1 (Ciona intestinalis) and NP_001024496.1 (Caenorhabditis elegans). Human α1 subunit paralogs were as previously described (Scholl et al., 2013).

Principal component analysis, analysis of relatedness, shared haplotypes and mutation age

Request a detailed protocol

Principal component analysis was performed as previously described (Lemaire et al., 2013). For analysis of close relatedness, genomic DNA from subjects 333-1, 1347-1, 1368-1, 1390-1, and 1393-1 was genotyped on Illumina Human 1M-Quad beadchips according to the manufacturer's instructions. Data were analyzed using a combination of GenomeStudio (Illumina) and PLINK v1.07 softwares (Purcell et al., 2007). Mean call rate was 95.7%. Kinship coefficients were calculated by using the robust algorithm in KING 1.4 (Manichaikul et al., 2010). For 1393-1, 1368-1 and 333-1, PLINK format was converted to BEAGLE format using Mega2 (Mukhopadhyay et al., 2005). Haplotypes flanking the CACNA1HM1549V mutation were phased by observed transmission in kindred 1393 and by maximum likelihood in kindreds 1368 and 333 using BEAGLE v.3.3.2 (Browning and Browning, 2007) and a reference panel (phase 1 1000Genomes project). Only SNPs called in at least two samples were used for imputation, and only called SNPs were used for determination of the shared interval. Four additional heterozygous variants in close proximity to CACNA1HM1549V were identified from the 1393-1 exome. For 1368-1 and 333-1, the inferred haplotype producing the largest shared interval was chosen for further analysis. Mutation age was determined from haplotypes including flanking 41 markers using ESTIAGE (Genin et al., 2004). Recombination fractions were calculated from marker distances and average recombination rate across the interval (2.9 cM/Mb, deCODE). Shared allele frequencies were from EUR population (1000 Genomes project), and mutation rate was set to 2 × 10−8.

Statistical analysis

Request a detailed protocol

For statistical analysis, a de novo mutation rate of 1.4 × 10−8 was assumed. The binomial probability of observing two or more de novo mutations at a specified position in a set of 41 cases (including one affected parent) was calculated and corrected for the target size of the human exome (24.75 Mb). The likelihood of observing three additional independent mutations at the identical position in 38 patients was calculated as a binomial probability from the assumed allele frequency.

The mutation burden per gene in the cohort of patients with PA was compared to that in a control cohort comprising 724 unaffected parents of patients with congenital heart disease sequenced to similar depth of coverage on the same exome platform (Zaidi et al., 2013) using Fisher's exact test.

Appendix 1

Case reports

K1347. Subject 1347-1 is a 9-year old male of European ancestry who was diagnosed with hypertension at age 3 years (blood pressures [BPs] 140–160/90–105 mmHg, >99th percentile). Evaluation revealed serum aldosterone 12–20 ng/dl, despite completely suppressed plasma renin activity (PRA) on repeated measures (<0.1 ng/ml/hr); aldosterone:renin ratio (ARR) > 120 to >200 ng/dl:ng/ml/hr. MRI of the abdomen revealed no adrenal or other mass. Further extensive evaluation for other causes of hypertension was unrevealing. He had normal echocardiogram, unremarkable serum chemistry including K+ of 3.8 mmol/l (nl 3.3–4.6), normal renal ultrasound, MR angiogram and computed tomography (CT) angiogram of the renal vessels, normal urine analysis, thyroid function, 24 hr urinary catecholamines, vanillylmandelic acid, homovanillic acid, metanephrines, unremarkable evaluation for congenital adrenal hyperplasia and normal urinary free 18-hydroxy cortisol. The subject was developmentally delayed (walked at age 14 months, spoke at age >2 years) and received physical and occupational therapy in early childhood. Neither parent was hypertensive, and there was no family history of early hypertension, cerebral hemorrhage, stroke or intracranial aneurysm. PRA remained low on treatment with spironolactone and isradipine, and BP was difficult to control. On atenolol, amlodipine and amiloride, he continued to have suppressed PRA, and aldosterone was normal to elevated. His blood pressure is currently well controlled on triple antihypertensive therapy with eplerenone, amlodipine, and chlorthalidone.

K1390. Subject 1390-1 is a 15-year old African American female. She was born prematurely at 28 weeks gestational age following a pregnancy complicated by maternal pre-eclampsia and prolonged rupture of membranes (birth weight 1331 g, length 38 cm, head circumference 28 cm, appropriate for gestational age). She developed respiratory distress, bradycardia, mild pulmonary artery branch stenosis, hyperbilirubinemia and necrotizing enterocolitis that responded to medical management. Developmental milestones were reported to be normal. At age 6 years, she was diagnosed with asthma and seasonal allergies. At age 7 years, she presented with headache, blurry vision and hyperactivity, and was diagnosed with hypertension (BP 150/90 mmHg, >99th percentile). Evaluation was remarkable for primary aldosteronism with elevated serum aldosterone (66 ng/dl) and suppressed PRA of 0.2 ng/ml/hr (ARR 330 ng/dl:ng/ml/hr). No adrenal masses or hypertrophy were observed on CT imaging. Renal ultrasound and echocardiography were normal. Follow up revealed hypokalemia (serum K+ 3.1 mmol/l), serum aldosterone of 34 ng/dl and PRA of 0.3 ng/ml/hr (ARR of 113 ng/dl:ng/ml/hr). Her current medications include hydrochlorothiazide, lisinopril, montelukast and loratadine. Her current height is 160 cm (38th percentile), and weight is 68.1 kg (89th percentile). Recent BP off medication was 165/105 mmHg.

The patient's family history was remarkable for early severe hypertension in her 38-year old mother (1390-2) who was diagnosed with hypertension (BP 215/115 mmHg) and hypokalemia at age 17 years. Two pregnancies were complicated by pre-eclampsia, a third resulted in a miscarriage following complication from appendicitis. Evaluation for secondary hypertension was consistent with primary aldosteronism. A CT scan at age 29 years showed mild left adrenal fullness without discrete adrenal mass. Adrenal venous sampling demonstrated aldosterone:cortisol ratios of 92 ng/dl:13.8 μg/dl = 6.67 ng/μg on the left side, 11 ng/dl:6.9 μg/dl = 1.59 ng/μg on the right side and 22 ng/dl:9.7 μg/dl = 2.27 ng/μg in the inferior vena cava. Direct renin was 3 μIU/ml (<5 suggestive of sodium/volume mediated hypertension).

This subject (1390-2) underwent unilateral adrenalectomy at age 29 years to attempt to mitigate severe hypertension with PA. Pathology demonstrated a 4.8 × 3.5 × 2 cm (normal 5 cm × 2.5 cm) specimen weighing 8 g (normal 2.8–5.5 g) (Neville and O'Hare, 1982). There was no macroscopic nodularity. Histology was significant for marked hyperplasia of the adrenal zona glomerulosa within a ∼0.1 cm cortex with all cell layers and cell types present. While the normal adrenal glomerulosa comprises only a few cell layers and is about 70 μm in depth, the glomerulosa of subject 1390-2 had ∼30 cell layers and was ∼300 μm in depth (Figure 4A–C). Clusters and trabeculae of glomerulosa cells infiltrated the fibrous capsule of the gland at multiple foci, with occasional micronodules just over the capsule. Staining with specific antibodies demonstrated that CACNA1H was expressed in the hypercellular glomerulosa of the patient (Figure 4D–F). Consistent with her germline mutation, hypertension recurred after surgery, requiring reinstitution of treatment. Her current medications are hydrochlorothiazide, lisinopril and metoprolol succinate, and recent BP on medication was 138/87.

The index case's father (1390-3), brother (1390-4) and maternal grandfather (1390-10) are normotensive. While the maternal grandmother (1390-5) was diagnosed with adult-onset hypertension, her aldosterone was normal (16 ng/dl), with non-suppressed PRA (18.92 ng/ml/hr) (Table 2).

K1368. Subject 1368-1 is a 19-year old male of European ancestry. His birth weight was 3740 g. Perinatal history was unremarkable. He underwent pyloromyotomy due to pyloric stenosis at age 5 weeks, and was hospitalized for respiratory distress at age 7 months. At age 8 years, he was found to be hypertensive, and evaluation at age 9 years revealed BPs of 130–140/80–90 mmHg (>99th percentile systolic; >95th percentile diastolic). Serum aldosterone was 20 ng/dl, PRA <0.2 ng/ml/hr (ARR >100 ng/dl:ng/ml/hr), and urinary aldosterone 20 µg/24 hr (nl 2–20). Renal ultrasound and angiogram at age 9 were unremarkable, and no adrenal enlargement was noted. On treatment with lisinopril and amlodipine, BP was 120–130/60–65 mmHg at age 13 (>95th percentile systolic, >50th percentile diastolic). Serum K+ was 3.6 mmol/l, and total CO2 was 30 mmol/l. Repeat aldosterone on medication was 5 ng/dl, and PRA was 0.1 ng/ml/hr. Neurologic evaluation revealed attention deficit disorder, but no medication was started. Height at age 14 was 157.5 cm (10th percentile), and weight was 41 kg (fifth percentile). BP further improved to 118/74 mmHg at age 14 (>50th percentile); serum K+ was 3.8 mmol/l and total CO2 25 mmol/l. After diagnosis of a mild mitral valve prolapse, treatment with a beta-blocker was started, and amlodipine was discontinued.

The patient's family history was remarkable for a maternal uncle (1368-4) who was diagnosed with hypertension at age 24 (BP 200/100 by history). He was treated with hydrochlorothiazide. At age 51 years, on treatment with 12.5 mg hydrochlorothiazide, his BP was 120/80 mmHg, with aldosterone 11 ng/dl and PRA 1.2 ng/ml/hr (note that treatment with hydrochlorothiazide increases PRA), with serum K+ 3.8 mmol/l. The patient's mother was normotensive, with a home BP of 116/80 mmHg. There was no evidence of primary aldosteronism (aldosterone 8 ng/dl, PRA 4.73 ng/ml/hr, serum K+ 3.7 mmol/l. The maternal grandfather reportedly had hypokalemia and hypertension and a remote history of seizures, which had resolved. He died from hemorrhagic stroke at age 76 years.

K333. Subject 333-2 is a 35-year old male of European ancestry who was diagnosed with hypertension at age 9 years (BP 192/144 mmHg) with a history of headaches, enuresis, polyuria and polydipsia. Retrospectively, a BP of 160/80 prior to surgery for unilateral orchiopexy and left inguinal hernia repair at age 2 years was noted. Serum K+ was 3.7 mmol/l, Cl− 108 mmol/l (nl 95–105), and other serum electrolytes, creatinine and blood urea nitrogen were normal. Extensive evaluation including ultrasound, CT scan, angiogram and i.v. pyelogram did not reveal any renal or adrenal abnormalities. ECG and echocardiogram were normal. Aldosterone levels were 25 and 40 ng/dl, and renin was suppressed at <0.7 ng/ml/hr. A dexamethasone test (0.5 mg 4 times a day) did not change BP, but aldosterone after 36 hr decreased to 3.2 ng/dl, and PRA was 0.3 ng/ml/hr. The subject had normal 24-hr urine vanillylmandelic acid, free cortisol, 5-OH indoleacetic acid and 17-OH progesterone, serum corticosterone, dehydroepiandrosterone, deoxycorticosterone, progesterone, 17-OH pregnenolone, ACTH and TSH. At age 17 years, height was 178 cm (78th percentile), and weight was 75 kg (62th percentile). Treatment with spironolactone, and later minoxidil, atenolol, hydrochlorothiazide, and lisinopril was initiated. At age 35 years, height was 185 cm, and weight was 109 kg. BP was 124/65 mmHg, and serum K+ was 3.7 mmol/l on treatment with atenolol, hydrochlorothiazide, lisinopril, minoxidil, and potassium chloride.

Family history was significant for early-onset hypertension in the subject's father (333-1), who was diagnosed with hypertension at age 13 years, but had been hospitalized at age 5 years for evaluation of precocious puberty, with recorded BPs of 130–160/90–120 mmHg. He has been on antihypertensive medication since age 19 years. The paternal grandmother was also reportedly diagnosed with hypertension in her youth.

K1393. Subject 1393-1 is a 5-year old Hispanic male (height 111.8 cm, 72nd %ile, weight 20.9 kg, 82nd %ile). He presented at age 2 months with a viral illness, was admitted to rule out sepsis and found to be extremely hypertensive (BP 170s/100s mmHg, >99th percentile). Serum K+ was 4.1 mmol/l, Cl− 110 mmol/l, and other electrolytes and creatinine were normal. On echocardiogram, he had mild left ventricular hypertrophy without coarctation. A renal angiogram was normal. Aldosterone was elevated at 87.2 ng/dl, and PRA was suppressed at <0.6 ng/ml/hr. Laboratory evaluation for other causes of hypertension was unrevealing and included normal thyroid function test, 24-hr urine metanephrines, vanillylmandelic acid, homovanillylmandelic acid and tests for congenital adrenal hyperplasia. ECG at age 4 years showed right ventricular conduction delay and prominent mid precordial ventricular forces, and echocardiogram showed minimal concentric left ventricular hypertrophy without left ventricular outflow obstruction, systolic or diastolic dysfunction.

Treatment with propranolol, captopril, hydralazine and spironolactone was started, and aldosterone increased to 290 ng/dl, with renal vein renin <0.6 ng/ml/hr. Current medications include Enalapril, Spironolactone and Propranolol. There was no known family history of hypertension. The father (1393-3) had serum of K+ 3.9 mmol/l, low plasma renin of 0.81 ng/ml/hr and normal aldosterone of 9.3 ng/dl, with BP of 120/82 mmHg.

Data availability

The following data sets were generated
    1. Scholl
    et al. (2015) dbSNP/ClinVar submission
    Novel disease-associated variant has been deposited in dbSNP (accession number SCV000218508); the patient consent provided does not permit deposition of complete exome data.
    http://www.ncbi.nlm.nih.gov/clinvar/?term=SCV000218508
The following previously published data sets were used

References

    1. Conn JW
    (1955)
    Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome
    The Journal of Laboratory and Clinical Medicine 45:3–17.
    1. International Consortium for Blood Pressure Genome-Wide Association Studies
    2. Ehret GB
    3. Munroe PB
    4. Rice KM
    5. Bochud M
    6. Johnson AD
    7. Chasman DI
    8. Smith AV
    9. Tobin MD
    10. Verwoert GC
    11. Hwang SJ
    12. Pihur V
    13. Vollenweider P
    14. O'Reilly PF
    15. Amin N
    16. Bragg-Gresham JL
    17. Teumer A
    18. Glazer NL
    19. Launer L
    20. Zhao JH
    21. Aulchenko Y
    22. Heath S
    23. Sõber S
    24. Parsa A
    25. Luan J
    26. Arora P
    27. Dehghan A
    28. Zhang F
    29. Lucas G
    30. Hicks AA
    31. Jackson AU
    32. Peden JF
    33. Tanaka T
    34. Wild SH
    35. Rudan I
    36. Igl W
    37. Milaneschi Y
    38. Parker AN
    39. Fava C
    40. Chambers JC
    41. Fox ER
    42. Kumari M
    43. Go MJ
    44. van der Harst P
    45. Kao WH
    46. Sjögren M
    47. Vinay DG
    48. Alexander M
    49. Tabara Y
    50. Shaw-Hawkins S
    51. Whincup PH
    52. Liu Y
    53. Shi G
    54. Kuusisto J
    55. Tayo B
    56. Seielstad M
    57. Sim X
    58. Nguyen KD
    59. Lehtimäki T
    60. Matullo G
    61. Wu Y
    62. Gaunt TR
    63. Onland-Moret NC
    64. Cooper MN
    65. Platou CG
    66. Org E
    67. Hardy R
    68. Dahgam S
    69. Palmen J
    70. Vitart V
    71. Braund PS
    72. Kuznetsova T
    73. Uiterwaal CS
    74. Adeyemo A
    75. Palmas W
    76. Campbell H
    77. Ludwig B
    78. Tomaszewski M
    79. Tzoulaki I
    80. Palmer ND
    81. CARDIoGRAM consortium
    82. CKDGen Consortium
    83. KidneyGen Consortium
    84. EchoGen consortium
    85. CHARGE-HF consortium
    86. Aspelund T
    87. Garcia M
    88. Chang YP
    89. O'Connell JR
    90. Steinle NI
    91. Grobbee DE
    92. Arking DE
    93. Kardia SL
    94. Morrison AC
    95. Hernandez D
    96. Najjar S
    97. McArdle WL
    98. Hadley D
    99. Brown MJ
    100. Connell JM
    101. Hingorani AD
    102. Day IN
    103. Lawlor DA
    104. Beilby JP
    105. Lawrence RW
    106. Clarke R
    107. Hopewell JC
    108. Ongen H
    109. Dreisbach AW
    110. Li Y
    111. Young JH
    112. Bis JC
    113. Kähönen M
    114. Viikari J
    115. Adair LS
    116. Lee NR
    117. Chen MH
    118. Olden M
    119. Pattaro C
    120. Bolton JA
    121. Köttgen A
    122. Bergmann S
    123. Mooser V
    124. Chaturvedi N
    125. Frayling TM
    126. Islam M
    127. Jafar TH
    128. Erdmann J
    129. Kulkarni SR
    130. Bornstein SR
    131. Grässler J
    132. Groop L
    133. Voight BF
    134. Kettunen J
    135. Howard P
    136. Taylor A
    137. Guarrera S
    138. Ricceri F
    139. Emilsson V
    140. Plump A
    141. Barroso I
    142. Khaw KT
    143. Weder AB
    144. Hunt SC
    145. Sun YV
    146. Bergman RN
    147. Collins FS
    148. Bonnycastle LL
    149. Scott LJ
    150. Stringham HM
    151. Peltonen L
    152. Perola M
    153. Vartiainen E
    154. Brand SM
    155. Staessen JA
    156. Wang TJ
    157. Burton PR
    158. Soler Artigas M
    159. Dong Y
    160. Snieder H
    161. Wang X
    162. Zhu H
    163. Lohman KK
    164. Rudock ME
    165. Heckbert SR
    166. Smith NL
    167. Wiggins KL
    168. Doumatey A
    169. Shriner D
    170. Veldre G
    171. Viigimaa M
    172. Kinra S
    173. Prabhakaran D
    174. Tripathy V
    175. Langefeld CD
    176. Rosengren A
    177. Thelle DS
    178. Corsi AM
    179. Singleton A
    180. Forrester T
    181. Hilton G
    182. McKenzie CA
    183. Salako T
    184. Iwai N
    185. Kita Y
    186. Ogihara T
    187. Ohkubo T
    188. Okamura T
    189. Ueshima H
    190. Umemura S
    191. Eyheramendy S
    192. Meitinger T
    193. Wichmann HE
    194. Cho YS
    195. Kim HL
    196. Lee JY
    197. Scott J
    198. Sehmi JS
    199. Zhang W
    200. Hedblad B
    201. Nilsson P
    202. Smith GD
    203. Wong A
    204. Narisu N
    205. Stančáková A
    206. Raffel LJ
    207. Yao J
    208. Kathiresan S
    209. O'Donnell CJ
    210. Schwartz SM
    211. Ikram MA
    212. Longstreth WT Jr
    213. Mosley TH
    214. Seshadri S
    215. Shrine NR
    216. Wain LV
    217. Morken MA
    218. Swift AJ
    219. Laitinen J
    220. Prokopenko I
    221. Zitting P
    222. Cooper JA
    223. Humphries SE
    224. Danesh J
    225. Rasheed A
    226. Goel A
    227. Hamsten A
    228. Watkins H
    229. Bakker SJ
    230. van Gilst WH
    231. Janipalli CS
    232. Mani KR
    233. Yajnik CS
    234. Hofman A
    235. Mattace-Raso FU
    236. Oostra BA
    237. Demirkan A
    238. Isaacs A
    239. Rivadeneira F
    240. Lakatta EG
    241. Orru M
    242. Scuteri A
    243. Ala-Korpela M
    244. Kangas AJ
    245. Lyytikäinen LP
    246. Soininen P
    247. Tukiainen T
    248. Würtz P
    249. Ong RT
    250. Dörr M
    251. Kroemer HK
    252. Völker U
    253. Völzke H
    254. Galan P
    255. Hercberg S
    256. Lathrop M
    257. Zelenika D
    258. Deloukas P
    259. Mangino M
    260. Spector TD
    261. Zhai G
    262. Meschia JF
    263. Nalls MA
    264. Sharma P
    265. Terzic J
    266. Kumar MV
    267. Denniff M
    268. Zukowska-Szczechowska E
    269. Wagenknecht LE
    270. Fowkes FG
    271. Charchar FJ
    272. Schwarz PE
    273. Hayward C
    274. Guo X
    275. Rotimi C
    276. Bots ML
    277. Brand E
    278. Samani NJ
    279. Polasek O
    280. Talmud PJ
    281. Nyberg F
    282. Kuh D
    283. Laan M
    284. Hveem K
    285. Palmer LJ
    286. van der Schouw YT
    287. Casas JP
    288. Mohlke KL
    289. Vineis P
    290. Raitakari O
    291. Ganesh SK
    292. Wong TY
    293. Tai ES
    294. Cooper RS
    295. Laakso M
    296. Rao DC
    297. Harris TB
    298. Morris RW
    299. Dominiczak AF
    300. Kivimaki M
    301. Marmot MG
    302. Miki T
    303. Saleheen D
    304. Chandak GR
    305. Coresh J
    306. Navis G
    307. Salomaa V
    308. Han BG
    309. Zhu X
    310. Kooner JS
    311. Melander O
    312. Ridker PM
    313. Bandinelli S
    314. Gyllensten UB
    315. Wright AF
    316. Wilson JF
    317. Ferrucci L
    318. Farrall M
    319. Tuomilehto J
    320. Pramstaller PP
    321. Elosua R
    322. Soranzo N
    323. Sijbrands EJ
    324. Altshuler D
    325. Loos RJ
    326. Shuldiner AR
    327. Gieger C
    328. Meneton P
    329. Uitterlinden AG
    330. Wareham NJ
    331. Gudnason V
    332. Rotter JI
    333. Rettig R
    334. Uda M
    335. Strachan DP
    336. Witteman JC
    337. Hartikainen AL
    338. Beckmann JS
    339. Boerwinkle E
    340. Vasan RS
    341. Boehnke M
    342. Larson MG
    343. Järvelin MR
    344. Psaty BM
    345. Abecasis GR
    346. Chakravarti A
    347. Elliott P
    348. van Duijn CM
    349. Newton-Cheh C
    350. Levy D
    351. Caulfield MJ
    352. Johnson T
    (2011) Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk
    Nature 478:103–109.
    https://doi.org/10.1038/nature10405
  40. Book
    1. Neville AM
    2. O'Hare MJO
    (1982)
    The human adrenal cortex
    Berlin: Springer.
    1. Rossier MF
    2. Ertel EA
    3. Vallotton MB
    4. Capponi AM
    (1998)
    Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells
    The Journal of Pharmacology and Experimental Therapeutics 287:824–831.
    1. Schrier AD
    2. Wang H
    3. Talley EM
    4. Perez-Reyes E
    5. Barrett PQ
    (2001)
    alpha1H T-type Ca2+ channel is the predominant subtype expressed in bovine and rat zona glomerulosa
    American journal of Physiology Cell physiology 280:C265–C272.
    1. Stowasser M
    2. Bachmann AW
    3. Jonsson JR
    4. Tunny TJ
    5. Klemm SA
    6. Gordon RD
    (1995)
    Clinical, biochemical and genetic approaches to the detection of familial hyperaldosteronism type I
    Journal of Hypertension 13:1610–1613.

Article and author information

Author details

  1. Ute I Scholl

    1. Department of Genetics, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, United States
    2. Division of Nephrology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Contribution
    UIS, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article
    Competing interests
    The authors declare that no competing interests exist.

  2. Gabriel Stölting

    Institute of Complex Systems, Zelluläre Biophysik, Forschungszentrum Jülich, Jülich, Germany
    Contribution
    GS, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2339-0545

  3. Carol Nelson-Williams

    Department of Genetics, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, United States
    Contribution
    CN-W, Acquisition of data, Analysis and interpretation of data
    Competing interests
    The authors declare that no competing interests exist.

  4. Alfred A Vichot

    Department of Genetics, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, United States
    Contribution
    AAV, Acquisition of data, Drafting or revising the article
    Competing interests
    The authors declare that no competing interests exist.

  5. Murim Choi

    1. Department of Genetics, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, United States
    2. Yale Center for Mendelian Genomics, New Haven, United States
    Contribution
    MC, Analysis and interpretation of data, Drafting or revising the article
    Competing interests
    The authors declare that no competing interests exist.

  6. Erin Loring

    1. Department of Genetics, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, United States
    2. Yale Center for Mendelian Genomics, New Haven, United States
    Contribution
    EL, Ascertained and recruited subjects, Obtained samples and medical records, Acquisition of data
    Competing interests
    The authors declare that no competing interests exist.

  7. Manju L Prasad

    Department of Pathology, Yale University School of Medicine, New Haven, United States
    Contribution
    MLP, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article
    Competing interests
    The authors declare that no competing interests exist.

  8. Gerald Goh

    Department of Genetics, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, United States
    Contribution
    GG, Analyzed exome sequencing results, Analysis and interpretation of data
    Competing interests
    The authors declare that no competing interests exist.

  9. Tobias Carling

    Yale Endocrine Neoplasia Laboratory, Yale School of Medicine, New Haven, United States
    Contribution
    TC, Ascertained and recruited subjects, Obtained samples and medical records, Acquisition of data
    Competing interests
    The authors declare that no competing interests exist.

  10. C Christofer Juhlin

    1. Yale Endocrine Neoplasia Laboratory, Yale School of Medicine, New Haven, United States
    2. Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Contribution
    CCJ, Ascertained and recruited subjects, Obtained samples and medical records, Prepared DNA samples and maintained sample archives, Acquisition of data
    Competing interests
    The authors declare that no competing interests exist.

  11. Ivo Quack

    Division of Nephrology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Contribution
    IQ, Ascertained and recruited subjects, Obtained samples and medical records, Acquisition of data
    Competing interests
    The authors declare that no competing interests exist.

  12. Lars C Rump

    Division of Nephrology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Contribution
    LCR, Ascertained and recruited subjects, Obtained samples and medical records, Acquisition of data
    Competing interests
    The authors declare that no competing interests exist.

  13. Anne Thiel

    Division of Nephrology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Contribution
    AT, Acquisition of data, Analysis and interpretation of data
    Competing interests
    The authors declare that no competing interests exist.

  14. Marc Lande

    Division of Pediatric Nephrology, University of Rochester Medical Center, Rochester, United States
    Contribution
    ML, Acquisition of data, Drafting or revising the article
    Competing interests
    The authors declare that no competing interests exist.

  15. Britney G Frazier

    Madigan Army Medical Center, Tacoma, United States
    Contribution
    BGF, Ascertained and recruited subjects, Obtained samples and medical records, Acquisition of data
    Competing interests
    The authors declare that no competing interests exist.

  16. Majid Rasoulpour

    Connecticut Children's Medical Center, Hartford, United States
    Contribution
    MR, Ascertained and recruited subjects, Obtained samples and medical records, Acquisition of data
    Competing interests
    The authors declare that no competing interests exist.

  17. David L Bowlin

    Intermed Consultants Ltd, Edina, United States
    Contribution
    DLB, Ascertained and recruited subjects, Obtained samples and medical records, Acquisition of data
    Competing interests
    The authors declare that no competing interests exist.

  18. Christine B Sethna

    Department of Pediatrics, Cohen Children's Medical Center of New York, New Hyde Park, United States
    Contribution
    CBS, Ascertained and recruited subjects, Obtained samples and medical records, Acquisition of data
    Competing interests
    The authors declare that no competing interests exist.

  19. Howard Trachtman

    Department of Pediatrics, NYU Langone Medical Center, New York, United States
    Contribution
    HT, Ascertained and recruited subjects, Obtained samples and medical records, Acquisition of data
    Competing interests
    The authors declare that no competing interests exist.

  20. Christoph Fahlke

    Institute of Complex Systems, Zelluläre Biophysik, Forschungszentrum Jülich, Jülich, Germany
    Contribution
    CF, Analysis and interpretation of data, Drafting or revising the article
    Competing interests
    The authors declare that no competing interests exist.

  21. Richard P Lifton

    1. Department of Genetics, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, United States
    2. Yale Center for Mendelian Genomics, New Haven, United States
    Contribution
    RPL, Conception and design, Analysis and interpretation of data, Drafting or revising the article
    For correspondence
    richard.lifton@yale.edu
    Competing interests
    The authors declare that no competing interests exist.

Funding

National Institutes of Health (NIH) (Centers for Mendelian Genomics, 5U54HG006504)

  • Richard P Lifton

Howard Hughes Medical Institute (HHMI) (Investigator Program)

  • Richard P Lifton

Agency for Science, Technology and Research (A*STAR) (Scholarship)

  • Gerald Goh

Ministry of Innovation, Science, Research and Technology of the state of North Rhine-Westphalia (Rückkehrerprogramm)

  • Ute I Scholl

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We gratefully acknowledge and thank the patients and families whose participation made this research possible. We thank Dr Patricia Hidalgo, Dr Mathieu Lemaire and Samir Zaidi for helpful discussions, and the staff of the Yale Center for Genome Analysis and Mina Schwenk for technical assistance.

Ethics

Human subjects: Informed consent for participation was obtained from all research participants, and research protocols were approved by the institutional review board (IRB) at Yale University (8556 protocol, HIC# 9515008556). Specific consent for publication was not obtained because the work does not include identifying, or potentially identifying, information.

Copyright

© 2015, Scholl et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,291
    views
  • 710
    downloads
  • 269
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ute I Scholl
  2. Gabriel Stölting
  3. Carol Nelson-Williams
  4. Alfred A Vichot
  5. Murim Choi
  6. Erin Loring
  7. Manju L Prasad
  8. Gerald Goh
  9. Tobias Carling
  10. C Christofer Juhlin
  11. Ivo Quack
  12. Lars C Rump
  13. Anne Thiel
  14. Marc Lande
  15. Britney G Frazier
  16. Majid Rasoulpour
  17. David L Bowlin
  18. Christine B Sethna
  19. Howard Trachtman
  20. Christoph Fahlke
  21. Richard P Lifton
(2015)
Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism
eLife 4:e06315.
https://doi.org/10.7554/eLife.06315

Share this article

https://doi.org/10.7554/eLife.06315

Categories and tags

Research organism

Further reading

    1. Cell Biology
    2. Chromosomes and Gene Expression

    TPR is required for cytoplasmic chromatin fragment formation during senescence

    Bethany M Bartlett, Yatendra Kumar ... Wendy A Bickmore
    Research Article Updated

    During oncogene-induced senescence there are striking changes in the organisation of heterochromatin in the nucleus. This is accompanied by activation of a pro-inflammatory gene expression programme – the senescence-associated secretory phenotype (SASP) – driven by transcription factors such as NF-κB. The relationship between heterochromatin re-organisation and the SASP has been unclear. Here, we show that TPR, a protein of the nuclear pore complex basket required for heterochromatin re-organisation during senescence, is also required for the very early activation of NF-κB signalling during the stress-response phase of oncogene-induced senescence. This is prior to activation of the SASP and occurs without affecting NF-κB nuclear import. We show that TPR is required for the activation of innate immune signalling at these early stages of senescence and we link this to the formation of heterochromatin-enriched cytoplasmic chromatin fragments thought to bleb off from the nuclear periphery. We show that HMGA1 is also required for cytoplasmic chromatin fragment formation. Together these data suggest that re-organisation of heterochromatin is involved in altered structural integrity of the nuclear periphery during senescence, and that this can lead to activation of cytoplasmic nucleic acid sensing, NF-κB signalling, and activation of the SASP.

    1. Chromosomes and Gene Expression
    2. Evolutionary Biology

    The emergence and evolution of gene expression in genome regions replete with regulatory motifs

    Timothy Fuqua, Yiqiao Sun, Andreas Wagner
    Research Article

    Gene regulation is essential for life and controlled by regulatory DNA. Mutations can modify the activity of regulatory DNA, and also create new regulatory DNA, a process called regulatory emergence. Non-regulatory and regulatory DNA contain motifs to which transcription factors may bind. In prokaryotes, gene expression requires a stretch of DNA called a promoter, which contains two motifs called –10 and –35 boxes. However, these motifs may occur in both promoters and non-promoter DNA in multiple copies. They have been implicated in some studies to improve promoter activity, and in others to repress it. Here, we ask whether the presence of such motifs in different genetic sequences influences promoter evolution and emergence. To understand whether and how promoter motifs influence promoter emergence and evolution, we start from 50 ‘promoter islands’, DNA sequences enriched with –10 and –35 boxes. We mutagenize these starting ‘parent’ sequences, and measure gene expression driven by 240,000 of the resulting mutants. We find that the probability that mutations create an active promoter varies more than 200-fold, and is not correlated with the number of promoter motifs. For parent sequences without promoter activity, mutations created over 1500 new –10 and –35 boxes at unique positions in the library, but only ~0.3% of these resulted in de-novo promoter activity. Only ~13% of all –10 and –35 boxes contribute to de-novo promoter activity. For parent sequences with promoter activity, mutations created new –10 and –35 boxes in 11 specific positions that partially overlap with preexisting ones to modulate expression. We also find that –10 and –35 boxes do not repress promoter activity. Overall, our work demonstrates how promoter motifs influence promoter emergence and evolution. It has implications for predicting and understanding regulatory evolution, de novo genes, and phenotypic evolution.

    1. Chromosomes and Gene Expression
    2. Developmental Biology

    N-terminus of Drosophila melanogaster MSL1 is critical for dosage compensation

    Valentin Babosha, Natalia Klimenko ... Oksana Maksimenko
    Research Article

    The male-specific lethal complex (MSL), which consists of five proteins and two non-coding roX RNAs, is involved in the transcriptional enhancement of X-linked genes to compensate for the sex chromosome monosomy in Drosophila XY males compared with XX females. The MSL1 and MSL2 proteins form the heterotetrameric core of the MSL complex and are critical for the specific recruitment of the complex to the high-affinity ‘entry’ sites (HAS) on the X chromosome. In this study, we demonstrated that the N-terminal region of MSL1 is critical for stability and functions of MSL1. Amino acid deletions and substitutions in the N-terminal region of MSL1 strongly affect both the interaction with roX2 RNA and the MSL complex binding to HAS on the X chromosome. In particular, substitution of the conserved N-terminal amino-acids 3–7 in MSL1 (MSL1GS) affects male viability similar to the inactivation of genes encoding roX RNAs. In addition, MSL1GS binds to promoters such as MSL1WT but does not co-bind with MSL2 and MSL3 to X chromosomal HAS. However, overexpression of MSL2 partially restores the dosage compensation. Thus, the interaction of MSL1 with roX RNA is critical for the efficient assembly of the MSL complex on HAS of the male X chromosome.